Investor Presentaiton

Investor Presentation First nine months of 2018 Slide 86 - Oral sema 14 mg Empa 25 mg In PIONEER 2, oral sema proved a statistically significant reduction in HbA1c and weight at week 52 vs empagliflozin Mean change in HbA1c (%-point) Mean change in HbA1c Mean change in body weight (kg) Mean change in body weight (kg) Oral sema 14 mg Empa 25 mg 0.0 0.0 -1.0 -0.4 -0.8 -1.2 -2.0 0.8 -3.0 -4.0 -1.3* -3.8 • -4.7* -1.6 -5.0 -2.0 0 -6.0 26 Weeks 52 521 0 26 Weeks 52 521 1 Results illustrated by using the secondary statistical method called hypothetical estimand after 52 weeks of treatment: Treatment effect, if all participants followed the treatment without rescue medication (analysed by using Mixed Models for Repeated Measurements (MMRM)). The statistical method is consistent with e.g. the statistical method used for the SUSTAIN programme for subcutaneous semaglutide * Statistically significant versus empagliflozin Note: Mean baseline HbA1c: 8.1% sema: semaglutide; empa: empagliflozin Source: Presented at the Novo Nordisk investor event at American Diabetes Association, 78th Annual Scientific Sessions, Orlando, FL, USA novo nordisk

View entire presentation